Compare Dow Inc (DOW) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Davita Inc — how do they compare? Dow Inc trades at $28.52 (market cap $20.06B), while Davita Inc trades at $175.04 (market cap $11.28B). The key difference: Dow Inc is the larger of the two by market cap, and Dow Inc pays a 5.04% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 82 Days and Davita Inc for 113 Days on average.
| DOW | DVA | |
|---|---|---|
Market Cap | $20.06B | $11.28B |
Volume | 7,817,231 | 650,294 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $240.96 |
52-Week Low | $20.65 | $103.87 |
Typical Hold Time | 82 Days | 113 Days |
Enterprise Value | $35.75B | $24.00B |
Dividend Yield | 5.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $28.59, up 1.53% with bearish technical signals despite recent earnings beats. The chemical company faces fundamental challenges with negative net income margin (-3.13%) and declining revenue trends from $56.9B in 2022 to $40.0B in 2025. Analyst consensus shows mixed sentiment with 30.6% buy ratings but a $34.22 price target suggesting 20% upside. Recent dividend announcement of $0.35 provides income support while cash flow trends show operational improvement projected for 2026.
DOW presents a high-risk opportunity with significant valuation disconnect - low P/S ratio (0.48) contrasts with negative profitability metrics. The stock's appeal hinges on operational turnaround and margin recovery in 2026 projections. Key risks include persistent revenue declines, high debt levels (29.87% debt-to-asset ratio), and competitive pressures in chemicals sector. Current price near support at $28 creates tactical entry point for patient investors betting on management's execution.
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
